FOP News

Annual Report of the FOP Collaborative Research Project

The 26th Annual Report Is Here!

Read more Share

The 2017 FOP Lab Tour—Part 1

FOP Research Development and Partnerships Director, Adam Sherman, shares highlights of his recent travels to labs conducting FOP research across New England.

Read more Share

New FOP Clinical Trial to Begin in Japan

The IFOPA is encouraged to see a clinical trial for FOP beginning in Japan.

Read more Share

FOP Research at the University of Michigan

IFOPA Board Member, Gary McGuire, and his daughter, Natalie, recently visited Dr. Ben Levi at his lab to discuss the FOP research being performed at the University of Michigan.

Read more Share

Clementia Announces Symposium at the 8th International Conference on Children's Bone Health (ICCBH)

An important announcement from Clementia

Read more Share

Clementia Announces Preliminary Results of its Phase 2 Trial in Treatment of FOP

An important announcement from Clementia

The IFOPA is pleased to share this announcement from Clementia Pharmaceuticals: Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with FOP. Read more.

Share

Dr. Fred Kaplan To Receive NORD's Rare Impact Award

The National Organization for Rare Disorders (NORD) named Dr. Fred Kaplan among its 2017 honorees.

Read more.

Share

Regeneron Shares Updates on its Ongoing FOP Research Program

Potentially Promising Treatment for FOP

We are pleased to share a few exciting updates on our ongoing work to help improve the lives of people with FOP. 

Read more Share

Bipartisan Support

21st Century Cures Legislation Signed by President Obama

On December 7, the Senate followed the House of Representative's lead and signed the 21st Century Cures bill which is focused on developing treatments and cures for rare diseases; President Obama signed it on December 13. 

Read more Share

Three new Clementia sites now open for Part B of the Phase 2 Open-label Extension Trial

Approval of 3 New Sites!

The participation of individuals living with FOP in clinical studies and trials is key to FOP drug development efforts. 

Read more Share

Make a Difference

Donate Connect Fundraise
Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter